Unfractionated Heparin Market

Unfractionated Heparin Market New Trends, Market
Segmentation, Footprint With Their Financial
Condition By 2026
Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in
vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a
natural protein in the body, to block clot formation. UFH is administered to patient
intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be
administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their
size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when
taken orally.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1672
Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism
(PE), and venous thromboembolism (VTE) in patients with increased postoperative
complications. Unfractionated heparin is the preferred treatment for patients at high risk of
bleeding complications, owing to its short activity and reversibility and its reversible
anticoagulant effect. Additionally, UTH offers various advantages over other types of heparin,
owing to its ability to rapidly enter into the blood stream and less reliant to kidney for
extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross
the placenta, and thus is considered as safe for the fetus.
Unfractionated Heparin Market Drivers
Growth of unfractionated heparin market is increasing, owing to the increasing incidence of
thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and among
others. According to the data findings published in the Centers for Disease Control and
Prevention (CDC), in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year
in the U.S. due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE).
According to data published in the Circulation Research Journal: a journal of the American
Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with
increasing age. According to the same source, in the U.S., study estimated the age-stratified
incidence showing 143 per 100000 among ages 40 to 49 years, 200 per 100 000 among ages 50
to 59 years, 391 per 100000 among ages 60 to 69 years, 727 per 100000 among ages 70 to 79
years, and 1134 per 100000 among ages ≥80 years. Additionally, the low awareness regarding
the pulmonary embolism and deep-vein thrombosis showing the negligence towards the early
diagnosis of these condition. Moreover, healthcare regularity organizations are engaged in
increasing the awareness for the same, which will expected to drive the unfractionated heparin
market in near future.
Report includes chapters which deeply display the following deliverable about industry :
• Unfractionated Heparin Market Research Objective and Assumption
• Unfractionated Heparin Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Unfractionated Heparin Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Unfractionated Heparin Market, By Regions
• Unfractionated Heparin Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Unfractionated Heparin Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Unfractionated Heparin Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Unfractionated Heparin Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Unfractionated Heparin Market - Regional Analysis
On the basis of region, the unfractionated heparin market is segmented into North America,
Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading
position in the global unfractionated heparin market, owing to increasing prevalence of deep
venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the
Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000
to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of
people die within one month from diagnosis. Additionally, according to the same source,
around 5% to 8% of the U.S. population has one of several genetic risk factors, such as
inherited thrombophilias, which increases the risk for thrombosis.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1672
Unfractionated Heparin Market Competitive Landscape
Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen
AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO
Pharma A/S.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in vessels.

Download Report